Based on this, we have evaluated a pharmacological therapy based on ucf-101, a synthetic heterocyclic compound with neuroprotective effects in animal models of brain ischemia [24] that prevents XIAP cleavage and inhibition through the inhibition of Omi/HtrA2. The gene discussed is XIAP; the disease is brain ischemia.